Health Insurance

BioAlliance Pharma Obtains European Approval For Loramyc(R) Tablet Embossing And Extension Of Its Shelf Life To 36 Months

BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on therapy and supportive care in cancer and AIDS, announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis. The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance Pharma submitted a new drug application for Loramyc® to the Food and Drug Administration (FDA) in June 2009. BioAlliance Pharma will be able to harmonize Loramyc® production within those two key markets. BioAlliance Pharma also received European approval for extension of Loramyc®"s shelf life from 18 to 36 months. These two key industrial parameters are complementary assets for Loramyc® and will help optimizing manufacturing, storage and distribution costs. BioAlliance Pharma

Add your comment:

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):